Intravenous iron is recommended as first-line therapy in patients with clinically active IBD, severe anaemia (Hb < 10 g/dL), previous intolerance to oral iron, or when erythropoiesis-stimulating agents are required, demonstrating superior efficacy and faster response compared to oral preparations. The gene discussed is GSTM1; the disease is anemia.